PPACMAN Board Members @JosephMerolaMD and @AlexisOgdie recently published their findings on Guselkumab Treatment in Patients With Active Psoriatic Arthritis. Read the article here: https://t.co/CuoJm1urBQ #Dermatology #DermTwitter #Rheumatology #Rheum…
Clinically meaningful improvements in pain (40%) and physical function (30%) after 6 months in patients with PsA treated with guselkumab. Notable that ~90% of these pts were treatment refractory. From Penn's @AlexisOgdie and colleagues https://t.co/vg…
RT @ACR_Journals: In a real-world population of patients with treatment-resistant PsA, 6 months guselkumab treatment resulted in clinically…
In a real-world population of patients with treatment-resistant PsA, 6 months guselkumab treatment resulted in clinically meaningful improvement in pain and physical function in ~40% and ~30% of patients, respectively In ACROR https://t.co/HJjtQBidgu @Al…